Investors

Company profile

Flamel Technologies SA (NASDAQ: FLML) is a leading drug delivery company focused on the goal of developing safer, more efficacious formulations of drugs to tackle unmet medical needs.  Our product development pipeline includes biological and chemical drugs formulated with the Medusa® and Micropump® proprietary platforms.

Several Medusa-based products are at various clinical stages of development; Medusa’s lead internal product candidate IFN-α XL  (long-acting interferon alpha-2b) is currently the subject of a Phase 2 trial in HCV patients.
Intermediate analysis of that study was presented in November 2011 at the AASLD’s “Liver Meeting” in San Francisco: improved safety profile of IFN α-2b XL versus PegIntron during a 3-month course of combined therapy with weight-based ribavirin was confirmed.

The Company has drugs approved in the USA and in some European countries  (Coreg CR ® and Micropump aspirin, respectively) and manufactures Micropump-based products.

Flamel Technologies has collaborations with a number of leading pharmaceutical and biotechnology companies, including GlaxoSmithKline, Merck Serono and Pfizer.

Our versatile drug delivery platforms, Medusa and Micropump, may be used to address threshold formulation problems such as poor solubility, aggregation and instability for both chemical and biological drugs.

The Company’s innovative delivery platforms are used for the Life Cycle Management (LCM) of marketed products, including Biobetters, and the development of new compounds.

  • Medusa platform (injectable drugs) for the formulation and/or the extended release of biologics (including proteins, antibodies, and peptides) as, well as small molecules.
  • DeliVax™, Medusa’s vaccine application, permits the efficient formulation of vaccines.
  • Micropump platform (oral drugs) for the formulation and the controlled release of chemical drugs that are best absorbed in the small intestine.
  • LiquiTime™ allows the extended release liquid formulations of drugs for patients who have difficulty swallowing tablets or capsules, such as children and the elderly.
  • Trigger Lock™ may be used to create controlled release, tamper resistant formulations of narcotics and other drugs susceptible to abuse.

Financial Summary

  Three months ended September 30, 2011 ($K)
Total revenue 10,434
Total costs and expenses (9,194)
Income from operations 1,240
Net income 1,703
Cash and marketable securities position $ 29.5 MM
Diluted EPS $ 0.07
Basic shares outstanding 24.65 MM

Investors Contact

Charles Marlio
Director of Strategic Planning and Investor Relations
E-mail: ir@flamel.com  

Powered by